Systemic inflammation and the effects of short-term antibiotic treatment for PPM positive patients with stable COPD

References

• Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J. 1997;10(5):1137–1144.9163659
   PubMed Web of Science ®Google Scholar
• Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999;14(5):1015–1022.10596683
   PubMed Web of Science ®Google Scholar
• Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J. 1999;13(2):343–348.10065679
   PubMed Web of Science ®Google Scholar
• Barker BL, Haldar K, Patel H, et al. Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations. Chest. 2015;147(1):46–55. doi:10.1378/chest.14-076425103335
   PubMed Web of Science ®Google Scholar
• Marin A, Garcia-Aymerich J, Sauleda J, et al. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD. 2012;9(2):121–130. doi:10.3109/15412555.2011.63640722458940
   PubMedGoogle Scholar
• Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(9):991–998. doi:10.1164/rccm.200509-1525OC16474030
   PubMed Web of Science ®Google Scholar
• Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57(9):759–764. doi:10.1136/thorax.57.9.75912200518
   PubMed Web of Science ®Google Scholar
• Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J. 2004;23(5):685–691.15176680
   PubMed Web of Science ®Google Scholar
• Tumkaya M, Atis S, Ozge C, Delialioglu N, Polat G, Kanik A. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med. 2007;101(4):729–737. doi:10.1016/j.rmed.2006.08.02017002892
   PubMed Web of Science ®Google Scholar
• Wang H, Gu X, Weng Y, et al. Quantitative analysis of pathogens in the lower respiratory tract of patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:94. doi:10.1186/s12890-015-0094-z26286268
   PubMed Web of Science ®Google Scholar
• Singh R, Mackay AJ, Patel AR, et al. Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res. 2014;15:114. doi:10.1186/s12931-014-0114-125218165
   PubMed Web of Science ®Google Scholar
• Rosell A, Monsó E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005;165(8):891–897. doi:10.1001/archinte.165.8.89115851640
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(8):1090–1095. doi:10.1164/rccm.200210-1179OC12684248
   PubMed Web of Science ®Google Scholar
• Marin A, Monsó E, Garcia-Nuñez M, et al. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur Respir J. 2010;35(2):295–302. doi:10.1183/09031936.0012680819643939
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Haldar K, Barker B, et al. Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. Int J Chron Obstruct Pulmon Dis. 2015;10:1075–1083. doi:10.2147/COPD.S8009126089657
   PubMed Web of Science ®Google Scholar
• He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80(6):445–452. doi:10.1159/00032137420881376
   PubMed Web of Science ®Google Scholar
• Tan C, Huang H, Zhang J, He Z, Zhong X, Bai J. Effects of low-dose and long-term treatment with erythromycin on interleukin-17 and interleukin-23 in peripheral blood and induced sputum in patients with stable chronic obstructive pulmonary disease. Mediators Inflamm. 2016;2016:4173962. doi:10.1155/2016/417396227127346
   PubMed Web of Science ®Google Scholar
• Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax. 2015;70(10):930–938. doi:10.1136/thoraxjnl-2015-20719426179246
   PubMed Web of Science ®Google Scholar
• Prins HJ, Daniels JM, Lindeman JH, Lutter R, Boersma WG. Effects of doxycycline on local and systemic inflammation in stable COPD patients, a randomized clinical trial. Respir Med. 2016;110:46–52. doi:10.1016/j.rmed.2015.10.00926616678
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest. 2001;120(3):730–733. doi:10.1378/chest.120.3.73011555501
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139–1147. doi:10.1164/rccm.200801-145OC18723437
   PubMed Web of Science ®Google Scholar
• Blasi F, Bonardi D, Aliberti S, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther. 2010;23(3):200–207. doi:10.1016/j.pupt.2009.12.00220025989
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa110462321864166
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J. 2009;34(5):1066–1071. doi:10.1183/09031936.0019560819386683
   PubMed Web of Science ®Google Scholar
• Simpson JL, Powell H, Baines KJ, et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One. 2014;9(8):e105609. doi:10.1371/journal.pone.010560925148049
   PubMed Web of Science ®Google Scholar
• Siva R, Bafadhel M, Monteiro W, Brightling CE, Pavord ID. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2014;9:179–186. doi:10.2147/COPD.S5541924532969
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD; 2014 Available from: http://www.goldcopd.org/ Accessed 514, 2015).
   Google Scholar
• Soler-Cataluña JJ, Cosío B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48(9):331–337. doi:10.1016/j.arbres.2011.12.00922341911
   PubMed Web of Science ®Google Scholar
• Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc. 1975;50(6):339–344.1127999
   PubMed Web of Science ®Google Scholar
• Heineman HS, Chawla JK, Lopton WM. Misinformation from sputum cultures without microscopic examination. J Clin Microbiol. 1977;6(5):518–527.336644
   PubMed Web of Science ®Google Scholar
• Pye A, Stockley RA, Hill SL. Simple method for quantifying viable bacterial numbers in sputum. J Clin Pathol. 1995;48(8):719–724. doi:10.1136/jcp.48.8.7197560197
   PubMed Web of Science ®Google Scholar
• Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(4):356–361. doi:10.1164/rccm.200703-417OC17478618
   PubMed Web of Science ®Google Scholar
• Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype. Respir Med. 2013;107(1):10–22. doi:10.1016/j.rmed.2012.10.02423218452
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999;116(1):40–46. doi:10.1378/chest.116.1.4010424501
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Marín A, Monsó E, et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res. 2010;11:58. doi:10.1186/1465-9921-11-6220470372
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Anzueto A. Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(9):1052–1057. doi:10.1164/rccm.201302-0289PP23924286
   PubMed Web of Science ®Google Scholar
• Garcia-Nuñez M, Millares L, Pomares X, et al. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52(12):4217–4223. doi:10.1128/JCM.01967-1425253795
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Donaldson GC, Johnston SL, Openshaw PJ, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(8):871–876. doi:10.1164/rccm.200509-1489OC16456141
   PubMed Web of Science ®Google Scholar